Chinese Rheumatism Biobank Tracks Lupus Patients Over Time
Follows people with systemic lupus erythematosus to study early signs of organ damage.
Plain-language title generated from the registry record
Registry title: Chinese Rheumatism Biobank(CRB)
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with systemic lupus erythematosus (SLE) diagnosed within the last 2 years, who have active disease but no major organ damage.
- Sex
- All sexes can join.
- Disease stage
- SLE diagnosed 2 years ago or less. The disease is active (SLEDAI-2K above 0). No major organ involvement, such as lupus nephritis, brain, heart or lung disease, or vasculitis.
- Earlier treatment
- No systemic corticosteroids, plasmapheresis or IVIG in the last 3 months. No biologics in the last 3 months. No cyclophosphamide or CD20 inhibitors in the last 6 months.
Main reasons for not taking part
- Another autoimmune or autoinflammatory disease, such as rheumatoid arthritis or psoriasis
- Another condition that needs glucocorticoid treatment, such as asthma or Crohn's disease
- Pregnancy, planned pregnancy or breastfeeding
- Major organ problems at the start, such as kidney failure, heart failure, pulmonary hypertension or uncontrolled infection
- Cannot follow the long-term follow-up
Read by machine on 9 November 2026.
Where in China
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical CollegeBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Chinese SLE Treatment And Research Group
- Trial code
- NCT06887517
- Record updated
- 9 April 2025
- Original description
Early prediction of major organ damage in SLE needs to dynamically track the evolution of SLE patients before and after the onset of major organ damage, and analyze the microscopic molecular evolution patterns synchronized with the macroscopic pathophysiological changes.Read full original descriptionShow less
Chinese Rheumatism Biobank(CRB)
Early prediction of major organ damage in SLE needs to dynamically track the evolution of SLE patients before and after the onset of major organ damage, and analyze the microscopic molecular evolution patterns synchronized with the macroscopic pathophysiological changes.
Inclusion: Patients meet the 2012 SLICC classification criteria or 2019 ACR/EULAR classification criteria of SLE; Disease Duration ≤2 years since SLE diagnosis at baseline; Non-Organ-Threatening Disease, including BILAG-2004 categories A/B/C in neurological, cardiopulmonary, gastrointestinal, ophthalmic, renal, or hematological domains; Specifically excluded:; Renal: Cellular casts, hematuria (>5 RBC/hpf), proteinuria (>0.5g/24hr), pyuria (>5 WBC/hpf), or biopsy-proven lupus nephritis Neuropsychiatric: Seizures, psychosis, organic brain syndrome, cerebrovascular events Cardiopulmonary: Pulmonary arterial hypertension, myocarditis, pulmonary hemorrhage Vasculitis: Ulcerative/necrotizing lesions or biopsy-proven vasculitis Hematologic: Hemolytic anemia, thrombocytopenia (<100×10⁹/L) No acute thromboembolic events within 3 months; Treatment History:; No systemic corticosteroids, plasmapheresis, or IVIG within 3 months No biologics (e.g. belimumab, TNF-α inhibitors) within 3 months No cyclophosphamide or CD20 inhibitors within 6 months; Disease Activity: Clinical SLEDAI-2K >0 at screening/baseline.
Exclusion: SLE with concurrent conditions requiring glucocorticoid therapy, such as asthma or Crohn's disease; SLE with coexisting other autoimmune or autoinflammatory diseases, including but not limited to rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis; SLE with major organ dysfunction at baseline , including: impaired consciousness or cognitive decline, renal insufficiency, cardiac insufficiency (NYHA Class 3 or 4), pulmonary hypertension or interstitial lung disease, uncontrolled infections; Any condition deemed by investigators to compromise trial completion or pose significant risks; Pregnancy, planned pregnancy, or lactation; Inability to ensure compliance with long-term follow-up.